Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China.
Complement Ther Med. 2011 Jun;19(3):115-21. doi: 10.1016/j.ctim.2011.05.002. Epub 2011 May 25.
Explore the associations between the tongue appearances in Traditional Chinese Medicine (TCM) and effective response (ACR20 response based on American College of Rheumatology) in rheumatoid arthritis (RA) patients treated with Chinese medicine (CM) and western biomedical combination therapy (WM).
This study used the data from a previous multi-center randomized-controlled clinical trial. Data pertaining to tongue coating and tongue body color were collected. In order to simplify the tongue diagnosis for easily understood by biomedical professionals, only two typical tongue coating (white and yellow) and four typical tongue body colors (purple, pink, pale and red) were identified for this analysis. 170 cases with clear tongue coating and 198 cases with clear tongue body color in TCM treatment (Glucosidorum Tripterygll Totorum tablets and Yishen Juanbi tablets) group, 181 cases with identified tongue coating and 189 cases with identified tongue body color in WM treatment (diclofenec, methotrexate and sulfasalazine) group were included for the analysis. The ACR20 response at 12 weeks and 24 weeks were used as an outcome measure of efficacy. The effective rates in patients with different tongue appearances were analyzed with Chi-square method and the association between the changes of tongue coating/body color and the ACR20 response was analyzed with a repeated measures logistic regression analysis.
At 12 weeks, the ACR20 responses in the patients treated with CM and WM therapy were 33.6% and 53.0%, respectively, and at 24 weeks, they were 57.9% and 84.3%, respectively. RA patients with white tongue coating showed higher effective rate than those patients with yellow tongue coating in the treatment with WM intervention (p<0.05), and there was no difference in the patients with CM intervention. Further association analysis showed that TCM would be less effective for the patients with pale tongue body (p=0.0323), and WM would be less effective for the patients with purple or red tongue body (p=0.0291 and 0.0027, respectively).
TCM was less effective for the patients with pale tongue body, and WM was be less effective for the patients with purple or red tongue body, or white tongue coating. The results suggest that tongue coating and body color might be used to help identify a subset of RA patients both for CM and WM interventions.
探讨中药联合西医药生物治疗类风湿关节炎(RA)患者的舌象与有效应答(基于美国风湿病学会的 ACR20 应答)之间的关系。
本研究使用了一项多中心随机对照临床试验的数据。收集了舌象和舌体颜色的数据。为了便于生物医学专业人员理解,简化舌诊,本分析仅将两种典型的舌苔(白和黄)和四种典型的舌体颜色(紫、粉、淡和红)进行识别。在中药治疗组(雷公藤多苷片和益肾蠲痹丸)中,170 例舌苔清晰,198 例舌体颜色清晰;在西药治疗组(双氯芬酸、甲氨蝶呤和柳氮磺胺吡啶)中,181 例舌苔可识别,189 例舌体颜色可识别。将 12 周和 24 周时的 ACR20 应答作为疗效的衡量指标。采用卡方检验分析不同舌象患者的有效率,采用重复测量 logistic 回归分析舌苔/体颜色变化与 ACR20 应答的关系。
在 12 周时,中药和西药联合治疗组的 ACR20 应答率分别为 33.6%和 53.0%,在 24 周时,分别为 57.9%和 84.3%。西药治疗组白苔患者的有效率高于黄苔患者(p<0.05),而中药治疗组则无差异。进一步的关联分析表明,中药对淡舌体患者的疗效较差(p=0.0323),西药对紫舌体或红舌体患者的疗效较差(p=0.0291 和 0.0027)。
中药对淡舌体患者的疗效较差,西药对紫舌体或红舌体患者的疗效较差,或白苔患者的疗效较差。结果表明,舌象可能有助于识别中药和西药联合干预的 RA 患者亚群。